ES2086643T3 - Derivados de camptotecina solubles en agua. - Google Patents

Derivados de camptotecina solubles en agua.

Info

Publication number
ES2086643T3
ES2086643T3 ES92203263T ES92203263T ES2086643T3 ES 2086643 T3 ES2086643 T3 ES 2086643T3 ES 92203263 T ES92203263 T ES 92203263T ES 92203263 T ES92203263 T ES 92203263T ES 2086643 T3 ES2086643 T3 ES 2086643T3
Authority
ES
Spain
Prior art keywords
rent
perhalo
hydrogen
alcoxi
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92203263T
Other languages
English (en)
Inventor
Michael Joseph Luzzio
Jeffrey M Besterman
Michael G Evans
Peter Leslie Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Application granted granted Critical
Publication of ES2086643T3 publication Critical patent/ES2086643T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

EL INVENTO MUESTRA DERIVADOS DE CAMPTOTECINA SOLUBLES EN AGUA DE LA FORMULA (I), DONDE: N REPRESENTA EL ENTERO 1 O 2; Y I) R1 Y R2 REPRESENTAN INDEPENDIENTEMENTE, HIDROGENO, ALQUILO INFERIOR, CICLOALQUILO (C3-7), ALQUILO INFERIOR CICLOALQUILO (C3 INFERIOR ALCOXI INFERIOR; II) R1 REPRESENTA HIDROGENO, ALQUILO INFERIOR CICLOALQUILO (C3 7), ALQUILO INFERIOR CICLOALQUILO (C3 INFERIOR ALCOXI INFERIOR, Y R2 REPRESENTA ESENTA HIDROGENO, ALQUILO INFERIOR, ALQUILO INFERIOR PERHALO, CICLOALQUILO (C3 ALQUENILO INFERIOR, ALQUILO INFERIOR HIDROXI, ALCOXI INFERIOR, ALQUILO INFERIOR ALCOXI INFERIOR; O III) R1 Y R2 CONJUNTAMENTE CON EL NITROGENO LIGANTE FORMAN UN GRUPO HETEROCICLICO DE 3 A 7 ATOMOS SATURADO DE FORMULA (IA) DONDE : Y REPRESENTA O,S, CH2, NR4 DONDE R REPRESENTA HIDROGENO, ALQUILO INFERIOR, ALQUILO INFERIOR PERHALO, ARILO, ARILO SUSTITUIDO CON UNO O MAS GRUPOS ALQUILO INFERIOR, HALOGENO, NITRO, AMINO, AMINO ALQUILO INFERIOR, ALQUILO INFERIOR PERHALO, ALQUILO INFERIOR HIDROXI, ALCOXI INFERIOR,ALQUILO INFERIOR ALCOXI INFERIOR O; EPRESENTA HIDROGENO, ALQUILO INFERIOR, ALQUILO INFERIOR PERHALO, ALCOXI INFERIOR, ARILO, ARILO SUSTITUIDO CON UNO MAS GRUPO ALQUILO, ALQUILO INFERIOR PERHALO, ALQUILO INFERIOR HIDROXI, ALQUILO INFERIOR ALCOXI INFERIOR ; Y LAS SALES FARMACEUTICAMENTE ACEPTABLES CONSIGUIENTES; SU USO EN EL TRATAMIENTO DE TUMORES Y METODOS DE SU PREPARACION.
ES92203263T 1991-10-29 1992-10-23 Derivados de camptotecina solubles en agua. Expired - Lifetime ES2086643T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78427591A 1991-10-29 1991-10-29
US82672992A 1992-01-28 1992-01-28

Publications (1)

Publication Number Publication Date
ES2086643T3 true ES2086643T3 (es) 1996-07-01

Family

ID=27120258

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92203263T Expired - Lifetime ES2086643T3 (es) 1991-10-29 1992-10-23 Derivados de camptotecina solubles en agua.

Country Status (25)

Country Link
EP (1) EP0540099B1 (es)
JP (2) JP3020760B2 (es)
KR (1) KR100246154B1 (es)
CN (1) CN1072683A (es)
AP (1) AP306A (es)
AT (1) ATE136898T1 (es)
AU (1) AU657007B2 (es)
CA (1) CA2081580A1 (es)
CZ (1) CZ284023B6 (es)
DE (1) DE69209969T2 (es)
DK (1) DK0540099T3 (es)
ES (1) ES2086643T3 (es)
FI (3) FI104373B (es)
GR (1) GR3020120T3 (es)
HU (2) HU217970B (es)
IL (1) IL103571A (es)
IS (1) IS1708B (es)
MX (1) MX9206211A (es)
MY (1) MY108261A (es)
NO (1) NO302073B1 (es)
NZ (1) NZ244914A (es)
OA (1) OA09767A (es)
RU (1) RU2119921C1 (es)
SK (1) SK279298B6 (es)
TW (1) TW221994B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US6005537A (en) 1992-08-21 1999-12-21 Hitachi, Ltd. Liquid-crystal display control apparatus
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
EP0678025B1 (en) * 1993-01-15 1998-04-15 The Stehlin Foundation For Cancer Research Transdermal treatment of cancer with water-insoluble s-camptothecin of the closed lactone ring form
US5369127A (en) * 1993-04-21 1994-11-29 Allergan, Inc. 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
CA2161980A1 (en) * 1993-05-03 1994-11-10 William Dennis Kingsbury Substituted methylenedioxy¬3',4':6,7|indolizino-¬1,2-b|quinolinones
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
IT1269862B (it) * 1994-05-30 1997-04-15 Indena Spa Alcaloidi da mappia foetida, loro uso e formulazioni che li contengono
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
KR960029336A (ko) 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
US5496952A (en) * 1995-02-07 1996-03-05 North Carolina State University Method of making asymmetric DE ring intermediates for the synthesis of camptothecin and camptothecin analogs
US5670500A (en) * 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
AU6241796A (en) * 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
WO1997019085A1 (en) * 1995-11-22 1997-05-29 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
AU728178B2 (en) * 1996-06-27 2001-01-04 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
SG88737A1 (en) * 1996-10-30 2002-05-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
US6559309B2 (en) * 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
US6046209A (en) * 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
AU1400401A (en) * 1999-11-09 2001-06-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
KR100717916B1 (ko) 2000-02-28 2007-05-11 아방티 파르마 소시에테 아노님 캄프토테신 및 피리미딘 유도체를 포함하는 암 치료용 조성물
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
IL155509A0 (en) 2000-10-27 2003-11-23 Aventis Pharma Sa A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
WO2012050591A1 (en) 2010-10-15 2012-04-19 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
US20090104254A1 (en) 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
CN101407524B (zh) * 2007-10-09 2012-07-18 江苏先声药物研究有限公司 噁嗪骈喜树碱衍生物及其制备方法和用途
CN100592871C (zh) * 2008-03-14 2010-03-03 浙江林学院 一种杀虫剂组合物及其加工方法
ES2373172B1 (es) * 2010-07-16 2012-12-10 Consejo Superior De Investigaciones Científicas (Csic) Proceso de obtención de derivados solubles en agua de 20 (s) camptotecina como agentes antitumorales.
US8980909B2 (en) 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin
BR112020020466A2 (pt) * 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN110590796B (zh) * 2018-06-12 2022-07-15 青岛海洋生物医药研究院股份有限公司 喜树碱衍生物及其制备方法和应用
HUE065484T2 (hu) * 2019-04-26 2024-05-28 Immunogen Inc Camptothecin-származékok
EP4389752A4 (en) * 2021-08-19 2025-08-20 Hainan Simcere Zaiming Pharmaceutical Co Ltd CAMPTOTHECIN DERIVATIVE, PHARMACEUTICAL COMPOSITION AND THEIR USE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells

Also Published As

Publication number Publication date
HU217970B (hu) 2000-05-28
AU2738592A (en) 1993-05-06
JPH05222048A (ja) 1993-08-31
NO924158D0 (no) 1992-10-28
FI104373B (fi) 2000-01-14
FI20021090A7 (fi) 2002-06-07
CZ323792A3 (en) 1993-10-13
SK323792A3 (en) 1998-09-09
RU2119921C1 (ru) 1998-10-10
KR100246154B1 (ko) 2000-04-01
MX9206211A (es) 1993-05-01
GR3020120T3 (en) 1996-08-31
NO302073B1 (no) 1998-01-19
ATE136898T1 (de) 1996-05-15
NZ244914A (en) 1995-01-27
IL103571A (en) 1998-01-04
SK279298B6 (sk) 1998-09-09
TW221994B (es) 1994-04-01
FI924878A0 (fi) 1992-10-28
HUT65719A (en) 1994-07-28
JP3020760B2 (ja) 2000-03-15
AU657007B2 (en) 1995-02-23
JP2000109475A (ja) 2000-04-18
OA09767A (en) 1993-11-30
IL103571A0 (en) 1993-03-15
CA2081580A1 (en) 1993-04-30
NO924158L (no) 1993-04-30
DK0540099T3 (da) 1996-06-17
DE69209969T2 (de) 1996-09-12
EP0540099B1 (en) 1996-04-17
FI20021090L (fi) 2002-06-07
IS3936A (is) 1993-04-30
FI924878A7 (fi) 1993-04-30
FI982185L (fi) 1998-10-08
FI982185A0 (fi) 1998-10-08
AP306A (en) 1994-01-28
CN1072683A (zh) 1993-06-02
HU211349A9 (en) 1995-11-28
IS1708B (is) 1998-12-16
MY108261A (en) 1996-09-30
JP3229298B2 (ja) 2001-11-19
AP9200439A0 (en) 1992-10-31
CZ284023B6 (cs) 1998-07-15
HU9203384D0 (en) 1993-01-28
FI982185A7 (fi) 1998-10-08
DE69209969D1 (de) 1996-05-23
EP0540099A1 (en) 1993-05-05

Similar Documents

Publication Publication Date Title
ES2072959T3 (es) Derivados de aminoacido.
MY108261A (en) Water soluble camptothecin derivatives
NO931153L (no) Vannloeselige camptothecin-analoger fremgangsmaater og metoder
SE9103572D0 (sv) Organic salts of n,n'-diacetyl cystine
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
CY1108339T1 (el) Παραγωγα spiro(2h-1-benzopyran-2,4´-piperidine) ως αναστολεις της μεταφορας γλυκινης
FI925211A0 (fi) Isoxazol-4-karboxylsyraamider och hydroxialkylidencyanaettiksyraamider,laekemedel innehaollande dessa och anvaendning av dessa
CO4340623A1 (es) Derivados de indolina, metodo de preparacion y uso
ES8401075A1 (es) "procedimiento para preparar espiro (piperidino-oxobenzoxazinas) substituidas en posicion 1 anti-hipertensivas".
ES8304974A1 (es) "procedimiento para la preparacion de derivados de n-oxaciclil-alcohilpiperidina".
ES2040879T3 (es) Procedimiento de preparacion de derivados pirimidinilaminicos de piperidina.
JOP20250076A1 (ar) طرق لعلاج السرطان باستخدام مشتقات أيزو كوينولين أو 6-آزا-كوينولين
NO157643C (no) Anvendelse av sitronsyre for aa forhindre nedbrytning av farmasoeytisk taalbare syreaddisjonssalter av tienopyridinderivater.
RU93057572A (ru) 6,9-бис(аминозамещенные)-бензо(д)изохинолин-5,10-дионы, способы их получения, фармкомпозиция, способ лечения опухолей
SE7811455L (sv) 2-imino-imidazolidin-derivat
ES2061794T3 (es) Nuevos derivados de benzazepina.
BE816049A (fr) Derives d'acides benzodioxole-1
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
ES2000170A6 (es) Procedimiento para preparar 5,11-dihidro-6h-pirido(2,3-b)(1,4)-benzodiazepin-6-onas substituidas en posicion 11
ES8707738A1 (es) Un procedimiento para la preparacion de 1-metil-4,5-dihidroorotil-histidil-prolinamida
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
ES2043515A1 (es) Procedimiento para la preparacion de nuevos derivados de 1-difenilmetilpiperazina.
ES468127A1 (es) Un procedimiento para la preparacion de nuevos derivados de pirido (2,1-b) quinazolina
FI99013B (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten bentsimidatsolijohdannaisten valmistamiseksi
LV10098A (lv) Metilpiperazinazepina atvasinajumi to iegusana un lietosana

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 540099

Country of ref document: ES